Regular use can support your GLP-1 medication and contribute to better weight management through improved digestion and more stable blood sugar levels
Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
TB-500 is the 43-residue N-terminally acetylated thymosin beta 4 sequence, CHNOS, 4963.4 g/mol, CAS 77591-33-4
Bartelt K, Mast C, Deckert J, Gracianette M, Joyce B
The medication slows gastric emptying, which contributes to satiety but can also cause upper GI symptoms
The same was not true for subjects receiving a placebo